Abstract：
BACKGROUND: Candida auris is an emerging multidrug-resistant fungus associated with catheter-related bloodstream infections (CRBSI). In-vitro efficacy of chlorhexidine (CHX) and CHX/silver sulfadiazine-impregnated (CHX-S) antimicrobial central venous catheters (CVCs) against C. auris was investigated.
METHODS: Minimum inhibitory (MIC) and bactericidal (MBC) CHX concentrations were determined against nineteen C. auris isolates. To assess extraluminal efficacy, segments from CVCs impregnated externally (CHX-S1) and both externally and internally (CHX-S2) were plasma-conditioned for 1- and 6-days, and to assess intraluminal efficacy CHX-S2 CVCs were pre-conditioned with saline-lock for 6-days, followed by 24-hour C. auris inoculation and microbial adherence determination on impregnated and non-impregnated CVCs.
RESULTS: CHX inhibited all C. auris isolates with MIC and MBC range of 8-128 μg/mL. C. auris adherence was reduced on CHX-S1 and CHX-S2 extraluminally by 100% on day-1, 86.96%-100% on day-7, and intraluminally on CHX-S2 by 56.86%-90.52% on day-7.
CONCLUSIONS: CHX and CHX-S CVCs performance against C. auris observed in this study is consistent with antimicrobial benefits observed in prior pre-clinical and randomized controlled clinical studies.
CONCLUSIONS: CHX showed strong inhibitory and cidal effects on C. auris. CHX-S CVCs proved highly efficacious against this pathogen under in vitro conditions. Additional studies, however, are required to confirm clinical benefit.
METHODS: Minimum inhibitory (MIC) and bactericidal (MBC) CHX concentrations were determined against nineteen C. auris isolates. To assess extraluminal efficacy, segments from CVCs impregnated externally (CHX-S1) and both externally and internally (CHX-S2) were plasma-conditioned for 1- and 6-days, and to assess intraluminal efficacy CHX-S2 CVCs were pre-conditioned with saline-lock for 6-days, followed by 24-hour C. auris inoculation and microbial adherence determination on impregnated and non-impregnated CVCs.
RESULTS: CHX inhibited all C. auris isolates with MIC and MBC range of 8-128 μg/mL. C. auris adherence was reduced on CHX-S1 and CHX-S2 extraluminally by 100% on day-1, 86.96%-100% on day-7, and intraluminally on CHX-S2 by 56.86%-90.52% on day-7.
CONCLUSIONS: CHX and CHX-S CVCs performance against C. auris observed in this study is consistent with antimicrobial benefits observed in prior pre-clinical and randomized controlled clinical studies.
CONCLUSIONS: CHX showed strong inhibitory and cidal effects on C. auris. CHX-S CVCs proved highly efficacious against this pathogen under in vitro conditions. Additional studies, however, are required to confirm clinical benefit.
摘要：
背景：耳念珠菌是一种与导管相关性血流感染（CRBSI）相关的新兴多重耐药真菌。研究了氯己定（CHX）和CHX/磺胺嘧啶银浸渍（CHX-S）抗微生物中心静脉导管（CVC）对金黄色葡萄球菌的体外功效。
方法：测定了对19种耳C.auris分离株的最低抑制（MIC）和杀菌（MBC）CHX浓度。为了评估腔外疗效，从CVC外部（CHX-S1）和外部和内部（CHX-S2）的部分进行血浆调节1天和6天，为了评估管腔内疗效，CHX-S2CVC用盐水锁预处理6天，然后进行24小时耳弧菌接种和对浸渍和未浸渍的CVC的微生物粘附性测定。
结果：CHX抑制所有金丝酵母分离株，MIC和MBC范围为8-128μg/mL。在第1天时，CHX-S1和CHX-S2上的耳梭菌粘附性降低了100％，在第7天时为86.96％-100％，在第7天时，CHX-S2上的耳梭菌粘附性降低了56.86％-90.52％。
结论：在本研究中观察到的CHX和CHX-SCVC对金黄色葡萄球菌的表现与在先前的临床前和随机对照临床研究中观察到的抗菌益处一致。
结论：CHX对C.auris显示出较强的抑制和杀灭作用。在体外条件下，CHX-SCVC被证明对这种病原体非常有效。其他研究,然而,需要确认临床获益。
方法：测定了对19种耳C.auris分离株的最低抑制（MIC）和杀菌（MBC）CHX浓度。为了评估腔外疗效，从CVC外部（CHX-S1）和外部和内部（CHX-S2）的部分进行血浆调节1天和6天，为了评估管腔内疗效，CHX-S2CVC用盐水锁预处理6天，然后进行24小时耳弧菌接种和对浸渍和未浸渍的CVC的微生物粘附性测定。
结果：CHX抑制所有金丝酵母分离株，MIC和MBC范围为8-128μg/mL。在第1天时，CHX-S1和CHX-S2上的耳梭菌粘附性降低了100％，在第7天时为86.96％-100％，在第7天时，CHX-S2上的耳梭菌粘附性降低了56.86％-90.52％。
结论：在本研究中观察到的CHX和CHX-SCVC对金黄色葡萄球菌的表现与在先前的临床前和随机对照临床研究中观察到的抗菌益处一致。
结论：CHX对C.auris显示出较强的抑制和杀灭作用。在体外条件下，CHX-SCVC被证明对这种病原体非常有效。其他研究,然而,需要确认临床获益。
